| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
24,880,000 |
| Market
Cap: |
25.13(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.5165 - $5.01 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Eyenovia is a clinical stage ophthalmic company developing a pipeline of therapeutics based on its microdose array print (MAP™) platform technology, branded the Optejet®. MicroPine is Co.'s topical therapy for the treatment of progressive myopia, a back-of-the-eye ocular disease associated with pathologic axial elongation and sclero-retinal stretching. MicroLine is Co.'s pharmacologic treatment for presbyopia, a non-preventable, age-related hardening of the lens that causes the gradual loss of the eye's ability to focus on near objects and impairs near visual acuity. Mydcombi™ is Co.'s fixed combination formulation of tropicamide-phenylephrine for mydriasis.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
160,717 |
165,607 |
357,711 |
630,255 |
| Total Buy Value |
$176,411 |
$183,061 |
$635,654 |
$1,128,089 |
| Total People Bought |
1 |
2 |
6 |
7 |
| Total Buy Transactions |
3 |
4 |
15 |
27 |
| Total Shares Sold |
0 |
0 |
4,000 |
234,000 |
| Total Sell Value |
$0 |
$0 |
$13,560 |
$1,148,560 |
| Total People Sold |
0 |
0 |
1 |
2 |
| Total Sell Transactions |
0 |
0 |
1 |
5 |
| End Date |
2024-02-04 |
2023-11-03 |
2023-05-05 |
2022-05-05 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Rowe Michael M |
Vice President of Marketing |
• – – |
2018-09-25 |
4 |
B |
$4.27 |
$2,562 |
D/D |
600 |
1,000 |
2.66 |
- |
|
| Rowe Michael M |
Vice President of Marketing |
• – – |
2018-09-24 |
4 |
B |
$4.09 |
$818 |
D/D |
200 |
400 |
2.66 |
- |
|
| Mather Charles E Iv |
Director |
– • – |
2018-09-19 |
4 |
B |
$4.78 |
$14,340 |
D/D |
3,000 |
8,033 |
2.39 |
- |
|
| Mather Charles E Iv |
Director |
– • – |
2018-09-18 |
4 |
B |
$4.80 |
$4,800 |
D/D |
1,000 |
5,033 |
2.31 |
- |
|
| Clasby Jennifer G |
VP, Clinical Operations |
• – – |
2018-09-10 |
4 |
OE |
$1.95 |
$56,482 |
D/D |
28,965 |
28,965 |
|
- |
|
| Sun Anthony Y |
Director |
– • – |
2018-07-24 |
4 |
A |
$0.00 |
$0 |
D/D |
4,033 |
4,033 |
|
- |
|
| Lee Kenneth B Jr |
Director |
– • – |
2018-07-24 |
4 |
A |
$0.00 |
$0 |
D/D |
4,033 |
4,033 |
|
- |
|
| Mario Ernest |
Director |
– • – |
2018-07-24 |
4 |
A |
$0.00 |
$0 |
D/D |
4,033 |
146,770 |
|
- |
|
| Eshelman Fredric N |
Director |
– • • |
2018-07-24 |
4 |
A |
$0.00 |
$0 |
D/D |
4,033 |
1,277,461 |
|
- |
|
| Mather Charles E Iv |
Director |
– • – |
2018-07-24 |
4 |
A |
$0.00 |
$0 |
D/D |
4,033 |
4,033 |
|
- |
|
| Ianchulev Tsontcho |
Chief Executive Officer |
• • • |
2018-06-28 |
4 |
B |
$6.63 |
$39,780 |
I/I |
6,000 |
6,000 |
2.64 |
- |
|
| Gandolfo John P |
Chief Financial Officer |
• – – |
2018-06-28 |
4 |
B |
$5.86 |
$11,720 |
D/D |
2,000 |
2,000 |
2.74 |
- |
|
| Mario Ernest |
Director |
– • – |
2018-01-29 |
4 |
B |
$10.00 |
$900,000 |
D/D |
90,000 |
236,770 |
2.39 |
- |
|
| Yoshida Shuhei |
Director |
– • • |
2018-01-29 |
4 |
B |
$10.00 |
$1,000,000 |
I/I |
100,000 |
1,718,566 |
2.25 |
- |
|
| Senju Pharmaceutical Co., Ltd. |
10% Owner |
– – • |
2018-01-29 |
4 |
B |
$10.00 |
$1,000,000 |
D/D |
100,000 |
1,718,566 |
2.45 |
- |
|
| Labelle Curt H |
Director |
– • • |
2018-01-29 |
4 |
B |
$10.00 |
$100,000 |
D/D |
10,000 |
10,000 |
3.92 |
- |
|
| Eshelman Fredric N |
Director |
– • • |
2018-01-29 |
4 |
B |
$10.00 |
$3,350,000 |
D/D |
335,000 |
1,273,428 |
3.92 |
- |
|
| Ianchulev Tsontcho |
Chief Executive Officer |
• • • |
2018-01-29 |
4 |
B |
$10.00 |
$100,000 |
D/D |
10,000 |
18,749 |
3.23 |
- |
|
143 Records found
|
|
Page 6 of 6 |
|
|
0.07 (7.74%) 
